Pitch Introduction
The NeuraSim Shark Tank India pitch introduced a breakthrough in ophthalmological care by addressing Amblyopia, commonly known as ‘lazy eye.’ Appearing in Season 4, founders Doctor Ramesh, Abhi, and Girish presented their innovative product, BIVI, which utilizes Virtual Reality (VR) technology to rewire the brain’s connection with the weaker eye. With a bold ask of ₹1 Crore for 8% equity, the founders aimed to disrupt the traditional and often ineffective ‘patching’ method used for decades. The pitch highlighted the struggle of 15 million children in India suffering from this condition, offering a technology-driven solution that promises results 2 to 6 times faster than conventional therapies.
Business Overview
NeuraSim operates at the intersection of Medical Technology (MedTech) and digital therapeutics. Their flagship product, BIVI, is designed to treat Amblyopia, a neurological condition where the brain ignores signals from one eye, leading to significantly reduced vision and depth perception. While traditional treatments involve patching the stronger eye for months—a process that is often uncomfortable and poorly adhered to by children—NeuraSim uses an immersive VR environment to stimulate both eyes simultaneously through gamified exercises.
The company employs a dual business model targeting both clinics and end consumers. Hospitals and eye care centers can purchase the high-end VR device for their facilities, while a rental model named BV Home allows patients to continue their therapy at the convenience of their homes for a monthly fee. This B2B2C approach ensures that medical professionals supervise the initial therapy while providing a scalable solution for long-term patient compliance.
Product Details
The BIVI hardware consists of a lightweight 180-gram VR headset integrated with specialized software containing 9 different therapy modules. These modules offer 76 unique permutations of exercises that range from simple visual tracking to complex 3D coordination tasks. Unlike standard VR games, BIVI’s software provides dichoptic stimulation, meaning it sends different images to the left and right eyes, forcing the brain to integrate the signals and strengthen the weaker neural pathways. The gamified nature of the snowman ice-ball games and diamond-collecting ‘Shark’ missions ensures that children remain engaged for the recommended 20-minute sessions, solving the major hurdle of treatment compliance.
Market Position
NeuraSim holds a unique Market Position as one of the few Indian companies leveraging VR for specialized ophthalmological rehabilitation. Their primary competitive advantage is their US-granted patent for the specific process and hardware-software combination developed in collaboration with European partners. While traditional eye exercises exist, NeuraSim’s ability to offer quantifiable data tracking for doctors sets them apart. They are currently targeting the top 1% of the population affected by this disease, focusing on urban centers where technology adoption is higher and affordability for the ₹12,000 monthly rental model is feasible.
| Business Detail | Information |
|---|---|
| Company Name | NeuraSim Health |
| Founders | Dr. Ramesh, Abhi, Girish, Pradeep Walia |
| Product Type | VR Medical Device & Software |
| Price Range | ₹4.5 Lakhs (Clinic) / ₹12,000 (Home Monthly) |
| Primary Channel | B2B (Clinics) & B2B2C (Home Rental) |
| Headquarters | Bangalore, Karnataka |
About Founder’s
The founding team of NeuraSim combines deep clinical research with technical expertise and pharmaceutical sales experience. Doctor Ramesh, the lead researcher, is an academician with a PhD from BITS Pilani and has served as a Professor and Head at the Manipal Academy of Higher Education. His research into Glaucoma and public health drove the initial development of the technology through an Indo-European grant. Abhi, an optometrist and researcher who personally suffered from Amblyopia since childhood, serves as the primary inspiration for the product’s UX/UI design. Girish brings over 16 years of experience in the pharmaceutical industry, having worked with giants like Abbott Healthcare and Piramal.
- Dr. Ramesh: Clinician scientist with 10+ years of research at Sankara Nethralaya.
- Abhi: Optometrist who used the therapy to improve his own eye control in 24 days.
- Girish: Sales specialist with a background in Central Nervous System (CNS) portfolios.
- Pradeep Walia: US-based CTO and technical lead (not present in the Tank).
Shark’s and Founder’s QnA
Peyush Bansal: What percentage of Indians suffer from this condition of amblyopia and what problems does it cause?
Approximately 1% of Indians have it, which is about 15 million children and an equal number of adults. It is a neurodevelopmental disease where the brain ignores the weak eye. This leads to difficulty in depth judging, clumsiness, and trouble in low-light conditions. Visually, it often appears as a squint, which affects a person’s self-esteem and confidence.
Namita Thapar: What is the current standard treatment that doctors offer?
The first priority is glasses, followed by patching. In patching, you cover the strong eye to force the weak eye to work. However, vision only improves slightly, and it doesn’t solve the problem of stereopsis (3D vision) or contrast sensitivity. Our VR therapy addresses these difficult cases much more effectively.
Aman Gupta: How much will you sell this for to consumers and doctors?
The device for a clinic costs ₹4.5 Lakhs as a one-time cost. For home therapy, which we are launching now, it is a rental model. We believe customers are ready to pay between ₹15,000 to ₹18,000 for the convenience of home treatment. Currently, we are looking at a monthly rental of ₹12,000 for the device and software.
Anupam Mittal: Please tell us about your equity split?
I (Dr. Ramesh) have 33% equity. Our Polish partners, RemMed, also have 33% because we developed the product with them. Pradeep has 25%, and Girish has 8%. We have also planned a 6% ESOP pool through upcoming restructuring.
Vineeta Singh: Is your patent for the product or the process?
We have a US patent granted. The patent covers the technology we have built end-to-end—the combination of hardware and software developed with our grants. Our agreement with our Polish partners gives us a license for perpetuity to build and iterate for the Indian market.
Peyush Bansal: How many patients have you treated to date?
To date, we have improved the lives of over 800 children and adults. We saw results in mild to moderate cases within one month, while severe cases took around three months to show significant improvement.
Key Stats & Financials
At the time of the pitch, NeuraSim was pre-revenue, focusing primarily on R&D and pilot clinical trials. The company had been bootstrapped with internal funds and supported by a ₹45 Lakhs CCD (Convertible Capital Debenture) from the Research Innovation Circle of Hyderabad (RICH). The valuation cap for that previous round was ₹5 Crores.
Revenue and Profitability
- Lifetime Sales: ₹0 (Pre-revenue during pitch)
- Current Funding: ₹45 Lakhs via CCD
- Valuation Requested: ₹12.5 Crores
- Investment Request: ₹1 Crore for 8% equity
- Previous Valuation Cap: ₹5 Crores
Financial Breakdown
| Metric | Amount / Value |
|---|---|
| Total Grant Funding | ₹1 Crore |
| Pre-Seed Investment | ₹45 Lakhs |
| Clinic Device Price | ₹4.5 Lakhs |
| Monthly Home Rental | ₹12,000 |
| Research Investment | ₹30 Lakhs (Founders) |
| Target Monthly Revenue | ₹75 Lakhs (Post-Launch) |
Business Potential and TAM
The Total Addressable Market (TAM) for NeuraSim is expansive yet niche within the broader healthcare sector. In India alone, there are 15 million children suffering from Amblyopia. The global digital therapeutics market is projected to reach billions, with Ophthalmology being a key segment. However, as noted by the Sharks, the high cost of treatment—approximately ₹12,000 per month—narrows the immediate serviceable market to the urban upper-middle class. If the company can successfully drive down costs or partner with insurance providers, the potential to scale into Tier 2 and Tier 3 cities is massive.
Market Size Analysis
The Indian ophthalmology market is growing at a CAGR of 7.5%. Within this, the pediatric segment is particularly lucrative due to the rising awareness among parents. If NeuraSim captures just 1% of the 15 million affected children, they would have a user base of 1.5 Lakh patients. At a conservative annual revenue of ₹50,000 per patient, the market opportunity exceeds ₹750 Crores annually. The expansion into adult therapy and other binocular vision disorders could further double this TAM.
Growth Opportunities
- International Licensing: Expanding the US patent into sales in North American and European markets through partnerships.
- Software Diversification: Developing VR modules for Myopia control and Squint (Strabismus) correction.
- Government Partnerships: Integrating BIVI into public health initiatives to treat rural children at lower costs.
- Insurance Integration: Working with health insurance firms to include digital therapy in their coverage plans.
NeuraSim: Ideal Target Audience & Demographics
| Demographic | Details |
|---|---|
| Primary Age Group | 5 to 12 years (Pediatric) |
| Secondary Age Group | 18 to 45 years (Adult cases) |
| Interests | Healthcare, Gaming, Digital Wellness |
| Platform Preference | LinkedIn, Health Forums, Parenting Blogs |
| Geography | Tier 1 Cities (Bangalore, Mumbai, Delhi) | High-intent medical expenditure |
Marketing and Distribution Strategy
NeuraSim follows a medical-first marketing strategy, where clinical validation drives commercial trust. Instead of heavy consumer advertising, the company focuses on building relationships with ophthalmologists and pediatricians who act as the primary referrers for the BV Home model.
Customer Acquisition
The Customer Acquisition Cost (CAC) is managed through a referral-based incentive model. Doctors who prescribe the home therapy receive a portion of the service fee for their supervision, ensuring a steady stream of high-intent leads without high digital ad spend. NeuraSim also participates in medical conferences like AIOC (All India Ophthalmological Conference) to showcase their clinical data to professionals.
Distribution Channels
- B2B Direct: Selling machines directly to premium eye hospitals like Narayana Nethralaya and Sankara Nethralaya.
- Rental Network: Managing a fleet of home-use VR headsets distributed via logistics partners.
- D2C Inquiries: Leveraging their website for direct consultations and screening tests.
- Academic Institutions: Partnering with optometry colleges for research-led awareness.
Social Media and Content Strategy
Their social media presence is focused on educational content. They use YouTube to host case study videos of patients who have seen vision improvement. On LinkedIn, they focus on thought leadership in the HealthTech space, sharing updates on their US patent and clinical trial milestones to attract B2B partners and potential investors.
NeuraSim Shark Tank Deal Outcome
Despite the revolutionary technology, NeuraSim failed to secure a deal on Shark Tank India Season 4. The Sharks were unanimous in their praise for the clinical solution but were deeply concerned about the business structure and equity distribution. Anupam Mittal and Peyush Bansal both pointed out that the 33% equity held by a Polish partner and the absence of the CTO (Pradeep) were major red flags for an investment.
| Shark | Offer Detail |
|---|---|
| Namita Thapar | Out – Concerns over legal implications of patent and licensing. |
| Anupam Mittal | Out – Uncomfortable with equity structure and silent partners. |
| Peyush Bansal | Out – Market size too small for the current price point; team structure gaps. |
| Aman Gupta | Out – Felt the business lacked a strong marketer/full-time CEO. |
| Final Decision | No Deal |
NeuraSim Post-Show Update
Following their appearance on the show, NeuraSim has focused on its B2B2C expansion. According to YourStory, the company is successfully transitioning to a model where clinics provide home-based therapy, making the solution more economically viable. They have continued to refine their software and are working on further clinical validations to lower the barrier for entry into the mass market. While no new funding rounds have been publically announced since the pitch, their patient engagement has reportedly seen steady growth.
Business Analysis & Lessons
NeuraSim’s pitch was a classic example of high-tech clinical innovation meeting the harsh reality of business structuring. The product itself is world-class, solving a genuine problem with a high-margin digital solution. However, the founders struggled to defend a cap table where a significant portion of the company was owned by a foreign entity that wasn’t actively managing operations. This ‘silent partner’ risk is a common deterrent for venture capitalists who want to see the active founders holding the majority of the ‘skin in the game.’
Furthermore, the Pricing Strategy became a point of contention. While ₹12,000 per month is affordable for a sliver of the Indian population, it prevents the company from reaching the 15 million children they identified as their mission. For a medical technology to become a ‘unicorn,’ it must find a way to be either mass-market or high-value with an institutional buyer (government or insurance) that eliminates the individual affordability barrier.
Key Takeaways
- Equity Hygiene: Investors are wary of complex equity splits involving non-active international partners. Founders should clean up cap tables before pitching.
- Product-Market Fit: Even a patented, working product needs an accessible pricing model to achieve high scalability in a price-sensitive market like India.
- Team Presence: The absence of a key tech founder (CTO) during a high-stakes tech pitch can signal a lack of internal cohesion or commitment.
- Regulatory Clarity: For MedTech, having a ‘patent’ isn’t enough; you must clearly explain the licensing perpetuity and freedom to operate.
Pitch Conclusion
NeuraSim’s journey highlights the potential of VR in healthcare. While they left the Tank without a deal, the validation of their technology by the Sharks and their granted US patent provides a strong foundation for future growth. Their mission to cure Amblyopia remains vital, and as hardware costs drop, they may yet solve the affordability puzzle. If you enjoyed this breakdown, check out CureSee, Neuphony, and Matri.
[faq_accordian]